Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cjca.2024.09.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decision-making in valve reintervention: Redo-Transcatheter aortic valve replacement vs. explant surgery.
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:
Objective: Data remain limited on factors influencing the selection of redo-transcatheter aortic valve replacement (TAVR) versus surgical explant in patients with failing transcatheter heart valves. This study aimed to identify clinical and procedural factors guiding treatment decisions.
Methods: This single-center, retrospective study included all patients who underwent aortic valve reintervention following prior TAVR at a U.
Predicting the Surge in Valve-in-Valve Volume: A Comparative Study of Japan and the United States.
JACC Asia
August 2025
Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Background: Understanding trends in transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) utilization is essential for predicting valve-in-valve (ViV) TAVR usage, a viable option for failed bioprosthetic valves that presents a promising avenue for lifetime management of aortic stenosis.
Objectives: This study aimed to predict and compare the future annual ViV volume in the United States and Japan based on past and current TAVR/SAVR utilization under some underlying assumptions.
Methods: We developed a MATLAB-based Monte Carlo model engine to simulate the lifespan of bioprosthetic TAVR and SAVR valves.
Long-Term Outcomes in Valve-in-Valve TAVR: Expanding the Evidence From Registry to Practice.
JACC Cardiovasc Interv
August 2025
Medizinische Klinik I, University Hospital of Ludwig-Maximilians University, Munich, Germany. Electronic address:
Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.
JACC Cardiovasc Interv
August 2025
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Background: Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up.
Objectives: The aim of this study was to analyze the outcomes of AViV therapy using contemporary balloon-expandable valves (BEVs) in a large series with mid-term outcomes.
Methods: BEV AViV patients (June 2015 to December 2023) in the Society for Thoracic Surgeons (STS)/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were propensity matched to native transcatheter aortic valve replacement (TAVR) patients.
Retrograde Stenting of the Left Main Coronary Artery After Double Chimney Stenting in Previously Double Implanted Self-Expandable Transcatheter Heart Valves in a Degenerated Stentless Surgical Bioprosthetic Aortic Valve.
Catheter Cardiovasc Interv
August 2025
MEDICLIN, Herzzentrum Lahr, Lahr, Germany.
We report an interesting complex percutaneous coronary intervention (PCI) case in an 84-year-old male, with typical angina pectoris after previous coronary artery bypass graft (CABG) surgery and coronary double chimney stenting during a transcatheter aortic valve replacement (TAVR)-in-TAVR procedure with double self-expanding transcatheter heart valve (THV) in his degenerated stentless aortic surgical valve bioprosthesis.
View Article and Find Full Text PDF